Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Abstrakt

Randomly assigned 15,871 pathients who had had a recent acute coronary syndrom to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addition to the best available evidence-based care. In patients who had had a recent acute coronary syndrom dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.

Klíčová slova

• Dalcetrapib
• CETP inhibitor
• HDL-cholesterol
• acute coronary syndrom
• coronary heart disease